May 3 - 4, 2012    Boston MA , USA
Antibody-drug conjugates (ADCs) in late-stage clinical development have shown encouraging therapeutic effects against both solid tumors and hematological malignancies. Significant progress has been made through optimization of parameters including specificity, potency, linker technology, conjugate site design, and the stoichiometry and placement of drugs.  These sessions will showcase the design and discovery of next generation ADC’s, leveraging current knowledge from successful clinical candidates.

Venue

Location: The Boston Park Plaza
Contact Boston , USA

Related events

Antibody-Drug Conjugates May 2 - 3, 2015
Antibody-Drug Conjugates May 8 - 9, 2014
Antibody-Drug Conjugates May 2 - 3, 2013
Antibody-Drug Conjugates May 3 - 4, 2012
Antibody-Drug Conjugates May 12 - 13, 2011